Premium
Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder
Author(s) -
Ang Celina,
Chambers Ann F.,
Tuck Alan B.,
Winquist Eric,
Izawa Jonathan I.
Publication year - 2005
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2005.05716.x
Subject(s) - osteopontin , medicine , stage (stratigraphy) , transitional cell carcinoma , pathological , urology , carcinoma , oncology , disease , gastroenterology , pathology , cancer , bladder cancer , biology , paleontology
OBJECTIVE To measure plasma levels of osteopontin in patients with transitional cell carcinoma (TCC) of the bladder, and to determine if osteopontin levels relate to disease stage. PATIENTS AND METHODS Blood samples were collected from 72 consecutive patients with TCC. Clinical data were obtained from medical record reviews. Patients were divided into subgroups based on disease status (active vs inactive) and clinical and pathological stage of TCC (tumour, nodes and metastases staging system). Osteopontin levels were measured using an enzyme‐linked immunosorbent assay. RESULTS Plasma osteopontin levels were higher in patients with active TCC than in controls ( P = 0.035). Plasma osteopontin levels were not significantly different between patients with active and inactive TCC, but were higher in patients with metastases than in patients with active, clinically organ‐confined TCC ( P = 0.021). CONCLUSIONS Plasma osteopontin levels increase with tumour stage in TCC of the bladder. These findings suggest that larger, more extended studies on plasma osteopontin levels in patients with TCC are warranted.